Key Points Amgen offers an attractive dividend and significant upside potential. Vertex Pharmaceuticals is a great biotech ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Veteran biopharma executive, Michael P. Cooke, PhD, joins Stratus to accelerate development of its pioneering Stratus Prime™ hematopoietic stem cell platformCAMBRIDGE, Mass., June 02, 2025 (GLOBE ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform.

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Among the lung cancer population with EGFR mutations, patients with insertions at exon 20 (ex20ins) represent a significant unmet need segment. These patients often have poorer outcomes compared to ...